Verrica Pharmaceuticals Inc.VRCANASDAQ
Loading
Year-over-year SG&A expense growth
Percentile
P17
Within normal range
vs 5Y Ago
-0.1x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -13.68% |
| Q3 2025 | 6.22% |
| Q2 2025 | 0.05% |
| Q1 2025 | -10.43% |
| Q4 2024 | -38.58% |
| Q3 2024 | -2.66% |
| Q2 2024 | 1.12% |
| Q1 2024 | -3.86% |
| Q4 2023 | -15.25% |
| Q3 2023 | 237.78% |
| Q2 2023 | 37.46% |
| Q1 2023 | 35.43% |
| Q4 2022 | -18.75% |
| Q3 2022 | -24.13% |
| Q2 2022 | 1.07% |
| Q1 2022 | 4.17% |
| Q4 2021 | -37.76% |
| Q3 2021 | 9.79% |
| Q2 2021 | 9.30% |
| Q1 2021 | -32.61% |
| Q4 2020 | 109.96% |
| Q3 2020 | -9.02% |
| Q2 2020 | 2.45% |
| Q1 2020 | 24.14% |
| Q4 2019 | 15.00% |
| Q3 2019 | -2.76% |
| Q2 2019 | 1.53% |
| Q1 2019 | 8.19% |
| Q4 2018 | -11.14% |
| Q3 2018 | 47.06% |
| Q2 2018 | 153.85% |
| Q1 2018 | 212.03% |
| Q4 2017 | 32.77% |
| Q3 2017 | 101.69% |
| Q2 2017 | 114.55% |
| Q1 2017 | 0.00% |